A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.

We deliver transformative solutions that power real results. See how we can help.

Optimizing Supply Chain
Integrating Pharmacy
Maximizing Value-Based Care
Awards

Transforming healthcare is more than our objective, it’s in our DNA. We’re dedicated to ensuring better health is just the beginning.

At every level of leadership, Premier’s experts are driving healthcare forward.

Leadership
Board of Directors
Speakers Bureau

Premier is more than a GPO. Combining robust analytics with consulting and advocacy, we’re changing the healthcare landscape for the better.  

Collective purchasing power lowers costs across your organization.

Intelligence plus unparalleled analytics equals data-driven solutions.

It’s only impossible until it’s not. Premier and our team of experts are transforming care delivery.

Work with Premier members to lower costs, improve quality and safety and succeed in value-based care.

A voice for better healthcare policy is a voice for you.  

Working closely with our members, we’re developing products and services to solve your most complex challenges.

Lower costs, greater efficiencies and a healthier bottom line.

Proven practices that result in better outcomes.

Intersecting specialty drugs with better management and data-driven best practices.

Controlling your future with integrated care delivery practices.

More savings and ROI is a win-win.

Data diving to deliver insights you can act on.

Supporting healthcare transformation through the generation of real-world evidence.

Our most recent insights, articles and more, all in one place.  

Discover what leading healthcare providers are achieving through Premier membership.

Stay informed with our white papers, webinars and e-books.

Browse our blog for a taste of what’s new and what’s next in healthcare.

Premier’s perspectives have been solicited by nationally renowned publications. Read on.

Read Premier’s latest announcements.

Catch our policy statements and perspectives on the latest in DC.

Compelling stories from the front lines of America’s health systems.

Data Delivered: Collaborating with Pharma to Study Anticoagulant Use in COVID-19 Patients

MicrosoftTeams-image-2.png#asset:5383

Given the novelty of COVID-19 in the first year of the pandemic and the lack of extensive data on the disease, standard protocols, treatments and practices of care didn’t exist, with clinicians trying anything and everything to alleviate symptoms and improve outcomes, hoping something would work.

To drive to an effective therapy faster, Meitheal Pharmaceuticals, a manufacturer of generic injectable products, joined forces with Premier Applied Sciences® (PAS), the research and analytics division of Premier.

“At Meitheal, we continuously work towards bridging important gaps in healthcare,” said Tom Shea, CEO, Meitheal Pharmaceuticals. “Our partnership with Premier is a stepping stone in the global effort to find patterns that help inform treatment guidelines for COVID-19 care.”

PAS – part of Premier’s PINC AI™ technology and services platform – develops research, real-world evidence and clinical trials innovation for medical device, diagnostic and pharmaceutical companies. This includes:

Underpinning PAS’s healthcare improvement work is the Premier® Healthcare Database (PHD), comprised of over 20 years of de-identified data from more than 1,000 hospitals spanning multiple therapeutic areas and quality improvement areas. Currently, the PHD contains data from more than 1 billion patient encounters.

To help fuel COVID-19 research, the PAS team developed a Special Release of the PHD (PHD-SR) that shortened the data lag time from five months to two weeks, making it the ideal source of data for studying the disease. Today, the PHD-SR contains real-world data representing more than 2.1 million patient encounters with a positive COVID-19 diagnosis.

Meitheal selected the PHD-SR as the data source for its retrospective cohort study on the effect of anticoagulant use in COVID-19 patients discharged from U.S. hospitals between April 1, 2020 and November 30, 2020.

Anticoagulants are medications that prevent blood clots, which have been shown to worsen outcomes and lead to increased risk of death in individuals with COVID-19.

The Meitheal Study

Researchers tapped the comprehensive, timely PHD-SR to provide real-world evidence for profiling patients diagnosed with COVID-19. Hospital administrative data for 776 hospitals was included in the anticoagulant and COVID-19 analyses.

The primary objective of the study was to describe and compare the clinical and resource utilization outcomes of hospitalized inpatients diagnosed with COVID-19 and to assess the effects of anticoagulant treatment on outcomes.

Secondary objectives of the study included a description and comparison of demographic, visit, hospital and clinical characteristics between exposure groups.

Data from the PHD-SR was used to support all objectives.

The Findings

Researchers found:

  • Patients on a therapeutic dose of the anticoagulants enoxaparin or heparin have longer hospital lengths of stay, higher cost and worse clinical outcomes when compared to patients on a prophylactic dose.
  • When the therapeutic group is split by age, lab values suggest no difference in outcomes by age category

These findings support guidelines that prophylactic dosage is conditionally recommended for preventing blood clots in patients with COVID-19 and suggest that differences in outcomes by treatment dosage is not due to patient age.

The Power of Real-World Data and Insights

PAS is leading the way with the most comprehensive database of COVID-19-related data to help understand the disease’s clinical progression and impact on patient care.

The PHD will continue to provide life sciences partners like Meitheal the opportunity to use real-world data to conduct evidence-based studies of drugs and clinical outcomes in an effort to improve the overall quality, safety and cost-effectiveness of care.

In addition to life sciences organizations, PAS partners with academia, government agencies, and healthcare insurers and providers, enabling them with PHD data for analyses of drugs, devices, disease states, epidemiology, resource utilization, healthcare economics and clinical outcomes.

Ready to put our data to work for your organization? Get the details on all the capabilities of the PHD as they relate to COVID-19 data.

Want more? Discover how the PHD has fueled leading COVID-19 research conducted by the Centers for Disease Control (CDC), the National Institutes of Health (NIH) and others.

Login Register Change Registration